GMP IPO Watch
Speciality Medicines IPO Day 2: Pharma SME Eyes Global Expansion—Should You Prescribe it to Your Portfolio?
Mumbai-based Speciality Medicines Limited is currently live with its ₹29.14 crore SME IPO. Priced at ₹117–₹124, this 100% fresh issue is a strategic play to pivot from distribution to in-house R&D. With Day 2 bidding underway and a listing scheduled for March 30, we break down the subscription trends, the ₹0 GMP, and the long-term potential.
Live IPO tracking available
Check GMP movement, allotment details, subscription demand, and deeper IPO context for this company.
Use these shortcuts to keep exploring
The archive button opens all articles from this category. The IPO details button opens the live IPO page on your GMP site in a new tab.
1. The Business: From Middleman to Maker
Speciality Medicines isn't your average pharmacy distributor. They focus on high-value specialty formulations—drugs used for complex conditions like oncology (cancer), immunology, and neurology.
The Current Model: They currently act as a high-end wholesaler and exporter, reaching over 20 states in India and 35+ countries globally.
The Pivot: The primary reason for this IPO is to build an in-house R&D Center in Gujarat. This will allow them to develop their own products rather than just distributing others', significantly boosting their profit margins in the long run.
2. Subscription Status (Day 2 Midday Update)
As of March 23, 2026, the issue has seen a polarized response between institutional and retail investors:
Total Subscription: ~0.85x (Approaching full subscription).
NII (HNI) Category: 1.60x — This is the strongest segment, showing that "big ticket" investors are confident in the company's fundamentals.
Retail Category: 0.08x — Public participation remains low, likely due to the high entry barrier typical of SME IPOs.
QIB Category: 1.00x — Fully booked by institutional buyers.
3. IPO Timeline & Investment Details
Since this is a BSE SME listing, the lot sizes and investment amounts are higher than standard mainboard IPOs.
| Event / Detail | Important Dates & Info |
|---|---|
| IPO Closing Date | Tomorrow, Tuesday, March 24, 2026 |
| Price Band | ₹117 to ₹124 per share |
| Minimum Lot Size | 1,000 Shares |
| Minimum Investment | ₹2,48,000 (2 Lots for Retail) |
| Allotment Date | Wednesday, March 25, 2026 |
| Listing Date | Monday, March 30, 2026 (BSE SME) |
4. Grey Market Premium (GMP) Today
Current GMP: ₹0
Interpretation: The grey market is currently "flat," meaning the stock is expected to list near its issue price of ₹124. In the current volatile market, a ₹0 GMP isn't necessarily a "red flag"—it often indicates that speculators are staying away, leaving the field open for fundamental investors.
5. Financial Snapshot: A "Top-Line" Explosion
The company’s growth in the last year has been remarkable:
Revenue (FY25): ₹58.54 crore (More than double the ₹27.66 crore in FY24).
Profit (PAT): ₹8.61 crore (Up from ₹2.93 crore in FY24).
Efficiency: A very healthy Return on Equity (ROE) of 37.85% and a low Debt-to-Equity ratio of 0.17.
6. Investor Verdict: The Pros & Cons
The Bull Case (The "Pros"):
Low Valuation: At a P/E of 8.79x, it is priced much cheaper than industry peers like Remus Pharmaceuticals (~10x) or Trident Lifeline (~27x).
100% Fresh Issue: No promoters are selling their shares (no OFS). Every rupee raised goes back into the company's growth.
Asset-Light to R&D: The move into R&D could transform them from a low-margin distributor to a high-margin pharma player.
The Bear Case (The "Cons"):
SME Risk: SME stocks have lower liquidity, meaning it can be harder to sell your shares quickly after listing.
Geopolitical Sensitivity: With exports to 35+ countries, any global trade tension or supply chain issue hits their bottom line directly.
